Ipratropio Bromuro/Salbutamol Cipla

Ipratropium bromide and salbutamol, the active ingredients in Ipratropio Bromuro/Salbutamol Cipla, are bronchodilators presented as an inhalation solution for inhalation use. It treats bronchospasm associated with chronic obstructive pulmonary disease (COPD) and acute asthma in adult patients.

GNH USA supplies Ipratropio Bromuro/Salbutamol Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide/salbutamol is indicated for conditions involving airway bronchoconstriction.

- Chronic obstructive pulmonary disease (COPD): provides bronchodilation to relieve bronchospasm and improve airflow. - Acute asthma: rapidly relaxes airway smooth muscle to ease breathing during an asthma attack. - Bronchospasm associated with COPD: reduces airway resistance and helps maintain ventilation.

The inhalation product may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Cough or throat irritation. - Dry mouth or hoarseness. - Tremor or shakiness. - Palpitations or increased heart rate. - Headache. - Nausea.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Severe tachycardia or arrhythmia. - Hypokalemia. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Elevated blood pressure. - Acute respiratory distress.

Before using this inhalation product, consider the following safety measures.

- Contraindicated in patients with known hypersensitivity to either component. - Use with caution in individuals with cardiovascular disease, especially arrhythmias. - Monitor blood potassium levels in patients at risk of hypokalemia. - Assess for potential paradoxical bronchospasm, particularly after the first dose. - Avoid use in patients with severe narrow‑angle glaucoma. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Ipratropium bromide/salbutamol may interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective β‑blockers: can diminish bronchodilator response and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants: may increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Diuretics or corticosteroids: may potentiate hypokalemia. - Other bronchodilators (e.g., long‑acting β2‑agonists): risk of additive tachycardia. - Anticholinergic drugs: may enhance anticholinergic effects such as dry mouth. - Theophylline: possible increase in theophylline serum levels. - Antihistamines: may increase anticholinergic burden.